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ABSTRACT
Background: To evaluate the cost-effectiveness of tofacitinib in comparison to vedolizumab for the 
treatment of moderate-to-severe ulcerative colitis (UC) after failure or intolerance to conventional 
therapy (bio-naive) or first-line biologic treatment (bio-experienced), from the Spanish National 
Health System (NHS) perspective.
Methods: A lifetime Markov model with eight-week cycles was developed including five health states: 
remission, response, active UC, remission after surgery, and death. Response and remission probabilities 
(for induction and maintenance periods) were obtained from a multinomial network meta-analysis. 
Drug acquisition – biosimilar prices included – (ex-factory price with mandatory deductions), adminis-
tration, surgery, patient management, and adverse event management costs (€, year 2019) were 
considered. A 3% discount rate (cost/outcomes) was applied. Probabilistic and deterministic sensitivity 
analyses (PSA) were conducted.
Results: Tofacitinib was dominant versus vedolizumab (both in bio-naive and bio-experienced patients) 
entailing total cost savings of €23,816 (bio-naïve) and €11,438 (bio-experienced). Differences in quality- 
adjusted life-year (QALY) were smaller than 0.1 for both populations. PSA results showed that tofacitinib 
has a high probability of being cost-effective (bio-naïve: 82.5%; bio-experienced: 90.6%) versus 
vedolizumab.
Conclusions: From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly 
and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains.
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Ulcerative colitis (UC) is a chronic inflammatory bowel disease 
with impairment limited to the colon and rectum. The usual 
symptoms are diarrhea, rectal bleeding, urgency, tenesmus, 
and crampy abdominal pain [1]. In most patients, UC follows 
a course with alternating periods of remission and relapses [2]. 
The global incidence and prevalence of UC have been increas-
ing over time. It is more common in northern and western 
European countries as well as in industrialized countries such 
as the United States, Canada, and Australia [2,3]. In Spain, its 
prevalence is around 88.7 cases per 100,000 population, and 
its annual incidence is 5.7–8 cases per 100,000 population [4].
UC is associated with a high economic burden, especially in 
severe cases where hospitalizations and surgeries account for 
the majority of direct costs [5]. Surgery is not the cure, with 
a significant proportion of patients needing additional sur-
geries or hospitalizations due to post-surgical complications 
such as chronic pouchitis [6,7]. In the last years and due to the 
introduction and widespread use of expensive biologic thera-
pies, there has been a shift away from hospitalizations and 
toward pharmaceuticals as the predominant driver of direct 
health-care costs in IBD patients [8,9]. The impact of UC on 
patient quality of life and work productivity generates signifi-
cant indirect costs, which may even exceed direct health-care 
costs [5].
The main objective of management in patients with UC is 
to induce remission and maintain it over a long-term per-
iod, with no need for corticosteroids, in order to prevent 
disability and surgical procedures, limit the incidence of 
colorectal cancer, and improve quality of life [2]. Various 
pharmacological treatments are available for moderate-to- 
severe UC: conventional treatments (corticosteroids, thio-
purines and calcineurin inhibitors), conventional biologic 
treatments (tumor necrosis factor [TNF] inhibitors), new bio-
logic treatments (anti-integrins [vedolizumab], interleukin 
12/23 inhibitors [ustekinumab]) and Janus kinase inhibitors 
(tofacitinib) [10]. However, up to 15% of patients will 
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ultimately require surgical treatment (colectomy) due to 
treatment failure or the development of colorectal dysplasia 
or carcinoma [3].
Given the availability of various treatment options with 
different mechanisms of action, it is essential to choose the 
best treatment option for a patient based on his or her indi-
vidual needs and characteristics. To do this, contraindications 
for use, patients’ treatment intolerances, the rate of primary 
non-response, and the potential for secondary loss of 
response over time must be considered. Secondary loss of 
response to biologics can be associated with immunogenicity, 
which is especially relevant for TNF antagonists [11,12].
Consistent with several comparative network meta- 
analyses (NMAs) [13,14], tofacitinib, vedolizumab, and all 
other biologic treatments evaluated are considered safe and 
effective therapies recommended for the treatment of moder-
ate-to-severe active UC, both in induction and in maintenance 
and both in a bio-naive population and following biologic 
failure. Specifically, a recent study by Singh et al. [14] classified 
infliximab as the best drug for inducing remission and muco-
sal healing in bio-naive patients. It also found tofacitinib and 
ustekinumab to be the best treatments for inducing remission 
and mucosal healing in patients previously exposed to TNF 
inhibitors and possibly even more effective than vedolizumab 
and adalimumab in these patients [14].
Given the broad range of treatments for UC, comparative 
economic evaluation and positioning of innovative drugs such 
as tofacitinib and vedolizumab are currently of special interest to 
payers and to provide more evidence to support decision- 
making. It is important to clarify that ustekinumab, another 
drug with an innovative mechanism of action recently approved 
by the European Medicines Agency (EMA) for the indication of 
moderate-to-severe ulcerative colitis, was excluded from the 
study because, at the time of the analysis, this drug lacked 
a price and funding for this indication in Spain.
The objective of this study was to evaluate, from the per-
spective of a European Public Health System (Spain), the 
efficacy of the use of tofacitinib versus vedolizumab for the 
treatment of patients with moderate-to-severe active UC 
following failure, loss of response, or intolerance to conven-
tional treatment (bio-naive) or to an anti-TNF biologic treat-
ment (bio-experienced).
2. Patients and methods
2.1. Population
\This cost-effectiveness analysis considered patients with mod-
erate-to-severe active UC who did not exhibit a suitable 
response, experienced loss of response, or had an intolerance 
to conventional treatment, conventional biologic treatment, or 
new biologic treatments. Two subpopulations were identified 
based on prior treatment received: patients naive to biologics 
(bio-naïve) and patients having already been treated with anti- 
TNF biologics (bio-experienced). Their characteristics were 
based on the patients enrolled in the OCTAVE Induction 1 
and 2 studies [15] (mean age 41.2 years; 59.2% male). 
A patient weight of 71.93 kg was derived from the weighted 
mean weight of individuals over 40 years of age in Spain [16].
2.2. Economic model
A de novo Markov model was developed in Microsoft Excel to 
show the course of UC over time according to the treatment 
received (Figure 1). It was designed in line with previously 
published analyses on this disease [17,18] and following the 
current recommendations [19,20]. An expert panel composed 
of gastroenterologists and hospital pharmacists validated the 
parameters of the model and contributed information regard-
ing routine clinical practice.
Treatment consisted of two phases: induction and mainte-
nance. In the induction phase, the treatment objective is to 
induce response or remission of active UC. In the maintenance 
phase, the goal is to maintain that response or remission. Four 
health states in addition to death were considered: remission 
(Mayo score = 0–2 and all subscores ≤1), response (reduction 
in the Mayo Clinic score of at least 3 points and a decrease of 
at least 30% from the baseline score, with a decrease of at 
least 1 point on the rectal bleeding subscore or an absolute 
rectal bleeding score of 0 or 1), moderate-to-severe active UC 
(Mayo score ≥6), and remission following surgery.
An initial cohort of 1,000 patients with moderate-to-severe 
active UC transited between health states in 8-week cycles. 
Once they received induction treatment, they could exhibit 
clinical remission or clinical response or maintain active UC. 
The induction phase lasted 8 weeks, the same as that of the 
OCTAVE studies [15] and similar to that seen in other UC 
clinical trials (6–10 weeks) [14,21]. The treatment alternatives 
considered in the analysis were tofacitinib and vedolizumab. 
When patients did not achieve response during induction or 
experienced loss of response during maintenance, they dis-
continued the treatment. Bio-naive patients could receive 
a second line of biologic treatment following discontinuation 
of the initial treatment. The subsequent treatment following 
response failure was infliximab (Table 1). Patients with active 
UC in the maintenance phase remained in that health state 
until they died or underwent surgery. For the purposes of the 
analysis, although there are other indications of surgery, only 
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patients with active UC could be candidates for surgical treat-
ment, with the possibility of developing complications and 
achieving remission following surgery (Figure 1).
This analysis was performed from the perspective of the 
Spanish National Health System (NHS). The time horizon con-
sidered was the patient’s lifetime, with a maximum of 
60 years. A 3% annual discount was applied both for costs 
generated and for health outcomes. Treatment efficacy was 
evaluated using the incremental cost–effectiveness ratio 
(ICER) and the incremental cost–utility ratio (ICUR) and 
expressed in terms of cost per life year (LY) gained and cost 
per quality-adjusted life year (QALY), respectively. These ratios 
Figure 1. Diagram of Markov model and treatment sequences.
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were estimated using the differences in terms of costs and 
health outcomes between the alternatives studied. 
A willingness-to-pay threshold was set at €25,000/QALY to 
evaluate whether one alternative is cost-effective compared 
to another. This threshold is not an official one in Spain 
though the latest publications have suggested ranges of 
€20,000-€25,000/QALY [22] and, most recently, €25,000- 
€60,000/QALY [23].
2.3. Efficacy
Without direct comparisons between treatments, the relative 
efficacy of tofacitinib versus vedolizumab was obtained from 
a fixed-effects multinomial NMA, using placebo as 
a comparator for reference [24]. Probabilities of transition 
between the health states of response and clinical remission 
were calculated for the induction phase (response and remis-
sion at 8 ± 2 weeks) and the maintenance phase (response 
and remission at 52 ± 4 weeks) [24] (Table 1). The latter phase 
had two independent analyses depending on the design of 
the studies included: treat-through, where the induction- 
phase treatment was maintained, and re-randomized, in 
which some patients were randomized following the induc-
tion phase (Table 1). Given that, at the time of the study, there 
were no data for the treat-through analysis with vedolizumab, 
and the relative risk between vedolizumab and placebo 
available in the re-randomized analysis was applied for each 
population (bio-naive, bio-experienced).
For a better adjustment to first-year and long-term efficacy 
outcomes, probabilities for all treatments were adjusted to 
two periods: weeks 0–24 and weeks 24–52. This adjustment 
was based on a post-hoc analysis of the OCTAVE Sustain study, 
in which differences between the two periods in terms of 
remission and response were observed. In addition, 
the second period seemed to show a constant trend over 
time and that effect was better suited to long-term extrapola-
tion than that obtained over the entire period (weeks 0–52) 
(Table 1).
2.4. Adverse events, risk of surgery, and mortality
Rates of treatment-related serious adverse events were 
included based on induction and maintenance studies of the 
medicines considered [15,21,24–27], with no distinction 
between bio-naive and bio-experienced patients (Table 2). 
An annual rate of surgery in patients with active UC of 
1.44% was used in line with an extensive epidemiology 
study conducted in Spain [28]. Patient mortality was deter-
mined based on mortality rates in the general Spanish popu-
lation by age and gender [16]; in addition, a perioperative 
mortality rate of 1.18% was used in patients having under-
gone colectomy [29].
Table 1. Probabilities of transition to response and remission (induction and maintenance phases).
Efficacy of treatment alternatives
Probabilities of transition (network meta-analysis – weeks 0–52)
Bio-naive Bio-experienced
Treatment % SD (%) % SD (%)
Induction phase
From ‘No Response’ to ‘Response’
Tofacitinib 57.18 4.53 59.57 4.06
Vedolizumab 66.54 6.34 42.67 7.06
Infliximab 72.36 3.02 50.18 8.35
From ‘No Response’ to ‘Clinical Remission’
Tofacitinib 22.04 3.49 17.90 2.92
Vedolizumab 29.99 6.10 8.90 3.13
Infliximab 36.03 3.39 12.63 4.30
Maintenance phase
From ‘Response’ to ‘Response’
Tofacitinib 58.53 10.21 30.51 10.10
Vedolizumab 46.79a 5.09 36.81a 7.92
Infliximab 45.72 6.28 31.87 6.86
From ‘Response’ to ‘Clinical Remission’
Tofacitinib 46.67 10.45 17.34 7.88
Vedolizumab 40.25a 5.40 21.07a 6.01
Infliximab 34.22 5.87 18.07 5.16
Probabilities of transition for tofacitinib 5 mg (OCTAVE Sustain) for adjustment to weeks 0–24 and weeks 24–52
Bio-naive Bio-experienced
Initial state/final state Response (%)a Remission (%) Response (%)a Remission (%)
Maintenance weeks 0–24
Remission 31 70 27 64
Responsea 29 9 30 14
No response 40 20 43 23
Maintenance weeks 24–52
Remission 53 80 25 52
Responsea 12 7 20 31
No response 35 13 55 17
aResponse with no remission. SD: standard deviation. a) Assumption based on relative risk in terms of efficacy between vedolizumab and placebo in the re- 
randomized multinomial analysis. 
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2.5. Quality of life
Utility values drawn from the literature were incorporated to 
reflect quality of life for patients with UC according to health 
state [30,31]: remission (0.87), response (0.76), active UC (0.41), 
and post-surgery remission (0.68).
2.6. Costs
In accordance with the analysis’s perspective (that of the NHS), 
direct health-care costs were included (Table 2): pharmacolo-
gical costs, administration costs, disease management costs by 
health state, surgery costs, and serious adverse event manage-
ment costs. Unit costs were obtained from Spanish national 
healthcare cost databases [32,33]. Pharmacological costs were 
calculated based on the dosage regimens of the treatment 
alternatives described in the summaries of product character-
istics [34] and prices were expressed in terms of ex-factory 
price (EFP) [32], with application of the mandatory deductions 
according to Royal Decree Law 8/2010 [35], corresponding to 
a 7.5% discount on the price of tofacitinib and vedolizumab 
(infliximab does not have a mandatory deduction as it is 
included in the reference price system). The price of the 
biosimilar medicine was used, if available. In drugs adminis-
tered intravenously, the price per milligram was considered, 
with no vial wastage allowed (Table 2). Intravenous adminis-
tration costs were calculated based on the cost of nursing staff 
and the infusion time for the drugs (30–90 minutes for vedo-
lizumab and 150 minutes for infliximab, according to the 
expert panel). Oral administration was assigned no cost. 
Patient management cost by health state was determined 
based on health-care resources consumed, which for their 
part were determined by the expert panel according to clinical 
practice. Costs of surgery and its complications, including 
patient management following colectomy, were included in 
aggregate according to data from a real clinical practice study 
in Spain [36]. Adverse event costs were obtained from the cost 
per process in the record of discharges from the database of 
the Spanish Ministry of Health according to the ICD 9-CM code 
best matching each event [33,37].
2.7. Sensitivity analyses
Deterministic sensitivity analyses (DSAs) and probabilistic sen-
sitivity analyses (PSAs) were performed to evaluate the uncer-
tainty of the values for the parameters and the robustness of 
the model. Some scenario analyses were performed modifying 
values of the time horizon (5, 10, and 20 years), discount rate 
(0% and 5%), annual surgery risk (alternative value: 4.2% [38]), 
and perioperative mortality (range 0–2.9% [29]). Univariate 
and multivariate DSAs modified the following parameters by 
±20%: unit price of tofacitinib, unit price of vedolizumab, costs 
of administration, management by health state, surgery, and 
management of adverse events as well as utility values for 
health states. In the PSAs, the parameters (utility values, tran-
sition probabilities, risk of surgery, perioperative mortality, 
pharmacological costs, administration costs, patient manage-
ment costs, and adverse event costs) were simultaneously 
varied by performing 1,000 Monte Carlo simulations on the 
1,000-patient cohort evaluated. The parametric functions used 
were beta for utilities, surgery risk and mortality risk due to 
colectomy, gamma for costs, and Dirichlet for distribution 
probabilities.
3. Results
The total patient management costs for patients with moder-
ate-to-severe active UC are shown in Table 3. Treatment with 
tofacitinib in patients with moderate-to-severe active UC 
yielded a reduction in total costs compared to vedolizumab. 
In bio-naive patients, in the treatment sequence that started 
with tofacitinib, this reduction was €23,815.58 versus vedoli-
zumab, whereas in the bio-experienced patient population, 
the reduction in total costs with tofacitinib was €11,437.56. 
In both subpopulations, the differences in costs were mainly 
due to the fact that the pharmacological and administration 
costs of vedolizumab are substantially higher than for tofaci-
tinib, whereas for all other dimensions studied, the results for 
the two drugs were similar though they were slightly lower 
with tofacitinib in all cases.
Regarding health outcomes, similar gains in terms of LYs 
gained were observed due to the disease’s limited impact on 
patient survival, with differences between the treatment 
options of less than 0.0005 LYs gained. In terms of QALYs, 
the differences between tofacitinib and vedolizumab were 
somewhat higher in the bio-experienced population (0.042 
QALYs) (Table 3). In both the bio-naive and bio-experienced 
patient populations, treatment with tofacitinib was 
a dominant treatment alternative (lower costs and higher 
effectiveness) compared to vedolizumab (Table 3).
The results of the DSAs and scenario analyses did not show 
significant variations relative to the base case, especially in the 
bio-experienced population, in which tofacitinib always 
remained a dominant alternative (Figure 2, Table 3). In bio- 
naive patients, tofacitinib remained a dominant alternative, 
except when considering a shorter time horizon, a higher 
discount rate, or a higher surgery risk; these cases showed 
slight differences in QALYs while maintaining the cost savings 
associated with tofacitinib (Table 3). Other variables with 
greater impact on the results were the price of vedolizumab 
and tofacitinib and utility values. However, in these cases, 
tofacitinib was still a dominant alternative (Figure 2).
The results of the PSA showed that the probability of 
tofacitinib being a cost-effective alternative to vedolizumab 
for a willingness-to-pay threshold of €25,000/QALY was 82.5% 
in a bio-naive population and 90.6% in a bio-experienced 
population (Figure 3). The average costs and QALYs obtained 
in the PSA were -€10,997.79 and 0.062 QALYs for the bio-naive 
population and -€8,687.92 and 0.038 QALYs for the bio- 
experienced population, being tofacitinib a dominant alterna-
tive in both scenarios (Figure 3).
4. Discussion
This analysis showed that tofacitinib is a dominant – i.e. 
less costly and more effective – treatment alternative 
compared to vedolizumab in treating patients with mod-
erate-to-severe active UC, regardless of whether it is used 
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following failure with conventional treatment or following 
an anti-TNF biologic treatment. Tofacitinib yields 
a reduction in total costs per patient compared to vedo-
lizumab in both patient populations (bio-naive and bio- 
experienced) largely deriving from the pharmacological 
costs of the treatments. Among the most relevant findings 
were those related to administration costs: orally adminis-
tered treatments account for substantial savings in treat-
ment costs compared to intravenously administered 
alternatives, which require greater healthcare resource 
consumption. The results revealed little difference in all 
other costs analyzed, in which the cost of tofacitinib is 
shown to be slightly lower. Specifically, disease manage-
ment with vedolizumab results in a higher cost due to 
a higher number of patients who remain in a state of 
active UC and, therefore, with a higher probability of 
undergoing surgery compared to treatment with tofaciti-
nib. Concerning the difference in costs due to adverse 
events, the highest cost with vedolizumab derived from 
a higher incidence of serious infections, upper respiratory 
tract infections, and acute infusion reactions, according to 
the studies included. On the other hand, differences in 
QALYs are slight, with tofacitinib presenting quality- 
adjusted survival gains in both populations studied.
A recent cost-effectiveness analysis was published compar-
ing tofacitinib and biologic treatments, such as infliximab, 
adalimumab, golimumab, and vedolizumab, in anti-TNF naive 
patients with moderate-to-severe UC in Spain. In this 10-year 
analysis, vedolizumab and tofacitinib were the treatments with 
higher effectiveness, with an ICUR of €45,253/QALY of vedoli-
zumab compared to tofacitinib. Tofacitinib had differences in 
costs between -€13,596 and €68,043 and differences in effec-
tiveness between −0.30 and 0,98 QALYs, when compared with 
the biologic treatments [39]. This author recently published 
a budget impact analysis conducted in Spain according to 
which the use of tofacitinib results in savings of up to 
€3,600,177 after 5 years [40].
Internationally, cost–effectiveness analyses including tofaciti-
nib have indeed been published [41,42]. The results of these 
publications are consistent with the findings of this analysis. 
A study by Lohan et al. in the United Kingdom also analyzed 
two populations according to prior exposure to a TNF inhibitor. 
This study found cost reductions associated with tofacitinib ver-
sus infliximab and vedolizumab in both populations; tofacitinib 
Figure 2. Deterministic sensitivity analysis: tornado diagram (A: bio-naive, B: bio-experienced).
Figure 3. Probabilistic sensitivity analysis: cost-effectiveness plane (A: bio-naive, B: bio-experienced).
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was dominant in these two comparisons and cost-effective (< 
₤18,000/QALY) versus adalimumab and golimumab [41]. 
Another study evaluated the efficiency of tofacitinib in two 
regions (the United Kingdom and China) using biologic and 
conventional treatment sequences. The sequences with tofaciti-
nib and vedolizumab were the most cost-effective treatments in 
the United Kingdom, and the sequences with tofacitinib were 
the most cost-effective treatments in China. When sequences 
with a biologic were compared (similar to the bio-experienced 
analysis), tofacitinib was dominant compared to infliximab, vedo-
lizumab, and golimumab, yielding ratios of ₤11,819-₤22,515/ 
QALY versus adalimumab [42]. In line with these results, in an 
economic evaluation by Milev et al. [43], tofacitinib followed by 
infliximab was associated with a lower cost per patient per 
month compared to treatment with vedolizumab followed by 
infliximab, in a bio-experienced population. Another study was 
recently published in Greece, in which tofacitinib was dominant 
to vedolizumab in both bio-naive and bio-experience popula-
tions with a 97% probability of being cost-effective [44]. Finally, 
a cost-effectiveness analysis in Poland compared tofacitinib and 
other biologics with conventional treatment, being tofacitinib 
the most effective treatment in bio-experienced patients and 
infliximab in bio-naive patients [45].
This analysis did have some limitations. Given the absence of 
efficacy in direct comparison between the two alternatives, it 
was necessary to perform indirect comparisons using an NMA. 
As studies with a treat-through design with vedolizumab were 
not available at the time of the analysis, estimates had to be 
made based on the data available from studies with a re- 
randomized design. This model did not consider administration 
of conventional treatment following failure with a second line 
of biologic treatment or tofacitinib, which is included in some 
published analyses [17,41,42]. However, other existing models 
also do not incorporate conventional treatment [39]. The expert 
panel felt that the administration of conventional treatment 
following biologic treatments did not reflect routine clinical 
practice; what is typical is to switch to a new biologic treatment 
at the clinician’s discretion. In line with this approach, a study of 
patients with UC being treated with biologics was identified in 
which approximately half the patients who stopped treatment 
did not subsequently restart the same treatment or switch to 
another treatment [46]. The bio-naive patient population could 
only receive a second line of biologic treatment following fail-
ure with the first study treatment. To minimize the effects of the 
subsequent treatment, the same second-line treatment (inflix-
imab) was used in the two comparators, whose selection was in 
accordance with the opinion of the expert panel based on 
routine clinical practice. Hence, no further subsequent lines of 
treatment were used as they could obscure the effect achieved 
with the treatments to be evaluated and in view of the limited 
evidence for determining the efficacy of advanced lines of 
treatment. Finally, possible dose escalations included in the 
summary of product characteristics, which could lead to 
increased pharmacological costs for both treatments, were not 
considered.
Another matter to take into account is that treatments 
were considered in monotherapy, whereas it has been 
reported that a high percentage of patients being treated 
with vedolizumab take it in combination with azathioprine. 
This would increase the pharmacological cost of this alterna-
tive and could be linked to a higher risk of adverse events 
such as lymphoma, opportunistic infection, and non- 
melanoma skin cancer [47]. Furthermore, it should be noted 
that the OCTAVE trials on tofacitinib featured a stricter defini-
tion of remission (with the additional requirement of a rectal 
bleeding subscore of 0) than that used in the studies on 
vedolizumab, and also required a centralized and therefore 
more demanding endoscopy reading [15].
To reflect surgery risk in patients with moderate-to-severe 
active UC, a fixed annual colectomy rate was used throughout 
the analysis time horizon although in clinical practice surgery 
risk may have varied over time in these patients with active UC. 
However, in this case, the use of more recent data published in 
Spain was preferred. Finally, as a limitation of this study, it 
should be noted that while the study was under way, ustekinu-
mab, another biologic administered intravenously for the treat-
ment of moderate-to-severe active UC, was approved by the 
EMA. This drug was not included in the analysis as it lacked 
a price in Spain and reimbursement at the time of the study.
Overall, it is important to stress that the ultimate choice of 
a treatment for UC should be the result of a complete assess-
ment that includes patient characteristics, drug efficacy and 
associated risks, as well as management-derived costs [48]. 
Economic evaluations are of great utility in assessing 
a medicine’s therapeutic positioning.
5. Conclusions
From the perspective of the NHS, treatment with tofacitinib 
could be a cost-effective and dominant (less costly and more 
effective) alternative than vedolizumab for the management 
of patients with moderate-to-severe active UC following fail-
ure, intolerance, or loss of response to conventional or anti- 
TNF biologic treatment.
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